Starting the conversation

Allergan CEO Saunders wants industry to do more to meet its social contract

Brent Saunders, Chairman, President & CEO of Allergan plc, brought the concept of a social contract to the forefront of discussions about drug companies in September 2016 with a blog post and company statement about the company’s “bold social contract with patients.”

“The health care industry has had a long-standing unwritten social contract with patients, physicians, policy makers and the public at large,” Saunders wrote. “Basically, in this social contract patients understood that making new medicines required significant investment. At the same time companies, doing the hard, long and risky work of bringing new medicines to market, understood that they had to price medicines in a way that made them accessible to patients while providing sufficient profit to encourage future investment.”

He added: “Those who have taken aggressive or predatory price increases have violated this social contract!”

Most of the media attention to Allergan’s commitment to a social contract focused on access and pricing, especially the company’s commitment to limit itself to

Read the full 1598 word article

How to gain access

Continue reading with a
two-week free trial.